Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

@article{Worgall2008TreatmentOL,
  title={Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.},
  author={S. Worgall and D. Sondhi and N. Hackett and B. Kosofsky and M. Kekatpure and N. Neyzi and J. Dyke and D. Ballon and L. Heier and B. Greenwald and P. Christos and M. Mazumdar and M. Souweidane and M. Kaplitt and R. Crystal},
  journal={Human gene therapy},
  year={2008},
  volume={19 5},
  pages={
          463-74
        }
}
  • S. Worgall, D. Sondhi, +12 authors R. Crystal
  • Published 2008
  • Medicine
  • Human gene therapy
  • Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 10(12) particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2 CU h-CLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three… CONTINUE READING
    329 Citations
    Considerations for the Treatment of Infantile Neuronal Ceroid Lipofuscinosis (Infantile Batten Disease)
    • M. Sands
    • Medicine
    • Journal of child neurology
    • 2013
    • 5
    Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
    • 45
    Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations.
    • 43
    Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
    • 35
    • PDF
    Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.
    • 101
    • PDF

    References

    SHOWING 1-10 OF 51 REFERENCES
    CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis.
    • 124
    • PDF
    Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
    • 64
    Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
    • 59
    • PDF
    Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors.
    • 123
    Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
    • 140
    Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.
    • 108
    • Highly Influential